Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider John Fesko sold 1,438 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total transaction of $291,683.92. Following the sale, the insider directly owned 185,782 shares in the company, valued at $37,684,020.88. The trade was a 0.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
John Fesko also recently made the following trade(s):
- On Friday, May 1st, John Fesko sold 291 shares of Natera stock. The stock was sold at an average price of $206.16, for a total transaction of $59,992.56.
- On Monday, April 27th, John Fesko sold 1,688 shares of Natera stock. The stock was sold at an average price of $204.10, for a total transaction of $344,520.80.
- On Tuesday, March 10th, John Fesko sold 707 shares of Natera stock. The stock was sold at an average price of $204.13, for a total transaction of $144,319.91.
Natera Price Performance
NASDAQ:NTRA traded up $10.83 during mid-day trading on Thursday, hitting $213.94. 1,861,579 shares of the company’s stock were exchanged, compared to its average volume of 1,650,189. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36. The business has a fifty day moving average price of $201.85 and a 200 day moving average price of $215.63. The company has a market cap of $30.64 billion, a PE ratio of -131.25 and a beta of 1.57.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its holdings in shares of Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. State Street Corp raised its holdings in shares of Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after purchasing an additional 72,087 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Natera by 37.5% during the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after purchasing an additional 727,366 shares during the last quarter. Finally, Coatue Management LLC raised its holdings in shares of Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after purchasing an additional 2,463,008 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research analysts have issued reports on the stock. Wells Fargo & Company lifted their target price on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. BTIG Research decreased their target price on shares of Natera from $260.00 to $250.00 and set a “buy” rating for the company in a report on Monday, May 11th. JPMorgan Chase & Co. lifted their target price on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Morgan Stanley decreased their target price on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $256.60.
Get Our Latest Stock Analysis on NTRA
Natera Company Profile
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Articles
- Five stocks we like better than Natera
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
